Compound A–Meropenem Therapy for β-Lactamase Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing β-lactam antibiotics face challenges due to the emergence of multidrug-resistant bacteria, particularly those producing β-lactamases such as Class D and metallo-β-lactamases, which current inhibitors like clavulanic acid, sulbactam, and tazobactam fail to effectively inhibit, leading to reduced efficacy against infections like hospital-acquired pneumonia and ventilator-associated pneumonia.
Innovation Solution
A combination therapy involving an oxo-substituted compound (Compound A) and meropenem is administered intravenously to enhance the activity of meropenem against β-lactamase-producing bacteria, including serine-β-lactamases and metallo-β-lactamases, by specific dosing frequencies and ratios, achieving effective plasma concentrations and AUC values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing β-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam) are used, then Class A β-lactamases are inhibited, but Class D and metallo-β-lactamases are not effectively inhibited
Solution Approach 1:
The patent develops a boronic acid derivative that functions as a universal inhibitor against multiple classes of β-lactamases (Class A, C, D, and metallo-β-lactamases), replacing the need for class-specific inhibitors. This multi-functional compound addresses the limitation of existing inhibitors that are effective only against specific β-lactamase classes.
Solution Approach 2:
The invention modifies the chemical structure by introducing a boronic acid group with specific substituents (oxo-substituted phenyl or naphthyl groups at the para position) to enhance the compound's ability to inhibit diverse β-lactamases. The structural parameters are optimized to achieve broad-spectrum inhibition while maintaining selectivity.
2Strength
If β-lactam agents are used alone, then broad antibacterial spectrum and strong bactericidal activity are achieved, but resistance develops due to β-lactamase production
Solution Approach 1:
The boronic acid derivative acts as an intermediary substance that binds to and inactivates β-lactamases, preventing these enzymes from degrading the β-lactam antibiotic. This mediator approach allows the β-lactam agent to maintain its bactericidal activity against resistant bacteria that produce β-lactamases.
Solution Approach 2:
The invention converts the harmful effect of β-lactamase production (which causes resistance) into a beneficial target for inhibition. By designing a compound that specifically targets and inactivates β-lactamases, the harmful resistance mechanism is transformed into a vulnerable point that can be exploited therapeutically.
3Reliability
If combination therapy with oxo-substituted compound and meropenem is administered, then activity against metallo-β-lactamases is enhanced, but dosing frequency and plasma concentration control become critical
Solution Approach 1:
The patent establishes specific dosing intervals (every 8 hours or every 12 hours) to maintain effective plasma concentrations of the oxo-substituted compound. This periodic administration schedule ensures that the compound remains at therapeutic levels to inhibit metallo-β-lactamases throughout the treatment period.
Solution Approach 2:
The dosing regimen is designed based on pharmacokinetic parameters (AUC, Cmax, half-life) to maintain plasma concentrations above the minimum inhibitory concentration for the target bacteria. This feedback-based dosing strategy ensures optimal therapeutic effect while minimizing the risk of resistance development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively inhibits a broad spectrum of β-lactamases, enhancing meropenem's activity against multidrug-resistant bacteria, including Acinetobacter baumannii and Pseudomonas aeruginosa, thereby treating infections like complicated urinary tract infections and hospital-acquired pneumonia.
Implementation Method 1
A combination therapy involving an oxo-substituted compound (Compound A) and meropenem is administered intravenously to enhance the activity of meropenem against β-lactamase-producing bacteria
Implementation Method 2
The combination therapy effectively inhibits a broad spectrum of β-lactamases, enhancing meropenem's activity against multidrug-resistant bacteria
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
The present disclosure provides a medicament and curing instructions for treating or preventing a bacterial infection. More specifically, the present disclosure is a medicament for treating or preventing a bacterial infection, the medicament comprising Compound A or a pharmaceutically acceptable salt thereof and meropenem or a pharmaceutically acceptable salt thereof, the medicament being characterized in that the medicament is administered to a subject intravenously. Alternatively, the present disclosure provides a medicament for treating or preventing a bacterial infection, the medicament comprising Compound A or a pharmaceutically acceptable salt thereof and meropenem or a pharmaceutically acceptable salt thereof, the medicament being characterized in that the Compound A or a pharmaceutically acceptable salt thereof is administered to a subject in such a manner that the activity of meropenem or a pharmaceutically acceptable salt thereof is improved compared with the case where meropenem or the pharmaceutically acceptable salt thereof is not used in combination.